Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data-Reference-Cited by-同舟云学术

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

Published:2010-07 Issue:7 Volume:105 Page:1574-1582
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Schreiber Stefan,Colombel Jean-Frédéric,Bloomfield Ralph,Nikolaus Susanna,Schölmerich Jürgen,Panés Julian,Sandborn William J

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg201078.pdf

Reference24 articles.

1. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.;Murch;Gut,1991

2. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation.;Braegger;Lancet,1992

3. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine.;MacDonald;Clin Exp Immunol,1990

4. Tumour necrosis factor alpha and interleukin 1 in relapse of CD.;Schreiber;Lancet,1999

5. Clinical course in Crohns disease: results of a five-year population-based follow-up study (the IBSEN study).;Henriksen;Scand J Gastroenterol,2007

Cited by 203 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epithelial barrier dysfunction and microbial dysbiosis: exploring the pathogenesis and therapeutic strategies for Crohn’s disease;Tissue Barriers;2024-08-26

2. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

3. Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort;Gastroenterology;2024-05

4. CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn’s disease;Insights into Imaging;2024-03-13

5. Optimal Management of Refractory Crohn’s Disease: Current Landscape and Future Direction;Clinical and Experimental Gastroenterology;2024-03